Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-CAV polypeptide analog, and corresponding cDNA (complementary deoxyribonucleic acid) and application thereof

A technology of analogs and drugs, applied in the field of peptide analogs, can solve problems such as intimal thickening, and achieve the effects of promoting interaction, simple purification process, and inhibiting occurrence and development.

Active Publication Date: 2016-05-25
NANTONG TENGZHONG MACHINERY
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows researchers to create an artificial protein called Myeloid Cell Line Associated Protein 1 (MCP1) that interact with certain proteins involved in cellular communication pathways such as integrins or receptors like VCAM-1. By modifying this molecular structure, it becomes possible to develop therapies targeting these interactions without affecting their functioning.

Problems solved by technology

The technical problem addressed in this patented study relates to prevention or reduction of cell growth within blood vessels called arteries leading to stenosis formation when delivering organs such as hearts from donor tissue into patients who require them due to congenital abnormalities associated with these defective veins.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-CAV polypeptide analog, and corresponding cDNA (complementary deoxyribonucleic acid) and application thereof
  • Anti-CAV polypeptide analog, and corresponding cDNA (complementary deoxyribonucleic acid) and application thereof
  • Anti-CAV polypeptide analog, and corresponding cDNA (complementary deoxyribonucleic acid) and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The present invention will be described in further detail below in conjunction with the accompanying drawings.

[0018] To achieve the above object, according to one aspect of the present invention, an anti-CAV polypeptide analogue is provided, the amino acid sequence of which is shown in SEQ NO.1 in the sequence listing. Anti-CAV peptide analogs are used to promote the interaction between TIMP-1 and MMP-14, inhibit the migration of VSMC after heart transplantation, and inhibit the development of CAV.

[0019] Correspondingly, the present invention also provides the application of the above-mentioned anti-CAV polypeptide analogs in the preparation of anti-angiopathic drugs of heart grafts.

[0020] Correspondingly, the present invention also provides the cDNA sequence of the above-mentioned anti-CAV polypeptide analogue, the sequence of which is shown in SEQ NO.2 of the sequence table.

[0021] Correspondingly, the present invention also provides the application of the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a polypeptide analog for resisting heart implant vasculopathy, and a corresponding cDNA (complementary deoxyribonucleic acid) and application thereof. On the basis of the establishment of the TIMP-1 and MMP-14 interaction structure field in CAV, the invention provides a method for producing a recombinant polypeptide analog myc HisA-TIMP-1[triangle102-217aa] by a gene engineering process. The polypeptide analog has the advantages of high expression efficiency and simple purification technique, and is beneficial to further large-scale preparation. The polypeptide analog can promote the interaction between TIMP-1 and MMP-14, inhibit the VSMC transfer after heart transplantation and inhibit the CAV from generation and development. The polypeptide analog can provide theoretical references for searching for effective intervention target spots for CAV and developing new therapeutic drugs. The polypeptide analog has very important development prospects for implementing long-term survival of heartmen after CAV clinical therapy.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Owner NANTONG TENGZHONG MACHINERY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com